RTRX Retrophin, Inc.

17.53
+0  (1%)
Previous Close 17.44
Open 17.40
Price To book 2.15
Market Cap 667.77M
Shares 38,093,000
Volume 307,373
Short Ratio 15.52
Av. Daily Volume 456,043

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing to commence mid-2017.
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
NDA filing due 2017
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 3 trial to be initiated 2H 2017.
Sparsentan
Focal segmental glomerulosclerosis (FSGS)

Latest News

  1. John A. Orwin Joins Retrophin Board of Directors
  2. Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
  3. Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA
  4. Mylan Receives Tentative Approval from FDA for HIV Therapy
  5. Alnylam's LDL-Lowering Drug Positive in Phase II Study
  6. Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
  7. Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
  8. Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
  9. Martin Shkreli’s former biotech company Retrophin is leaving Cambridge
  10. RETROPHIN, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
  11. RETROPHIN, INC. Financials
  12. Retrophin to Present at the Barclays Global Healthcare Conference
  13. Retrophin, Inc. :RTRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  14. Edited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMT
  15. Retrophin reports 4Q loss
  16. Retrophin reports 4Q loss
  17. RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  18. Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results
  19. Q4 2016 Retrophin Inc Earnings Release - After Market Close
  20. Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results